We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Launches New COVID-19 PCR Test with Reduced Turnaround Time Optimized for Mass Testing

By LabMedica International staff writers
Posted on 20 Jan 2022

Seegene, Inc. More...

(Seoul, Korea) has launched the new Allplex SARS-CoV-2 Fast PCR Assay that can deliver PCR results in just 60 minutes.

The assay is expected to reduce the total turnaround time to a third and expand testing capacity up to three times for hospitals and laboratories without additional instruments or compromise on accuracy, according to the company. The Allplex SARS-CoV-2 Fast PCR Assay targets three COVID-19 genes - E, RdRP, and N - to reliably detect COVID-19 regardless of the variants.

Reduction of the turnaround time can be attributed to the application of a novel enzyme developed by Seegene, which reduces PCR process time to half, as well as the company’s innovative extraction-free method that makes the Allplex SARS-CoV-2 Fast PCR Assay be available without the extraction of the sample preparation in PCR-based tests. This drastically reduces the total turnaround time for each result. As such, the new assay lessens the amount of hands-on processing time required, allowing facilities to triple their testing capacity in the same hour.

"This assay will be the optimized choice for laboratories and hospitals where they conduct large-scale testing as it helps them immediately expand the testing capacity with lessening the burden of healthcare workers," said Ho Yi, Chief Sales and Marketing Officer of Seegene. "For the time being, we plan to target large-scale testing markets in more than 60 countries all across the globe. The next step in our journey is to develop a new gold-standard molecular diagnostic assay that fully matches the speed of antigen tests with the same degree of accuracy as PCR test."

Related Links:
Seegene, Inc. 


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Neuron-derived extracellular vesicles carry many biomarker candidates for Alzheimer’s (S Chinnathambi et al., Brain Network Disorders (2025). doi.org/10.1016/j.bnd.2024.12.006)

Neuron-Derived Extracellular Vesicles Could Improve Alzheimer’s Diagnosis

Alzheimer’s disease is becoming increasingly common as global populations age, yet effective treatments for advanced stages remain limited. Early detection is therefore critical, but current diagnostic... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.